Study S003346

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy

ClinicalTrials.gov record

Registration

Registration: NCT07794397
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 200
Start: 2026-09
Primary completion: 2028-09
Lead sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions: Obstructive Sleep Apnea (OSA) and Obesity
Interventions: DRUG:HDM1005; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Percentage change in body weight from baseline at week 52 [52 week]
Change in AHI from baseline at week 52 [52 week]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.